These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26806807)

  • 1. Toward stratification of patients with pancreatic cancer: Past lessons from traditional approaches and future applications with physical biomarkers.
    Koay EJ; Amer AM; Baio FE; Ondari AO; Fleming JB
    Cancer Lett; 2016 Oct; 381(1):237-43. PubMed ID: 26806807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma.
    Craven KE; Gore J; Korc M
    Cancer Lett; 2016 Oct; 381(1):201-10. PubMed ID: 26723874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6: a villain in the drama of pancreatic cancer development and progression.
    Holmer R; Goumas FA; Waetzig GH; Rose-John S; Kalthoff H
    Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):371-80. PubMed ID: 25100121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal.
    Bijlsma MF; van Laarhoven HW
    Cancer Metastasis Rev; 2015 Mar; 34(1):97-114. PubMed ID: 25566685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
    Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
    Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer stroma: an update on therapeutic targeting strategies.
    Hosein AN; Brekken RA; Maitra A
    Nat Rev Gastroenterol Hepatol; 2020 Aug; 17(8):487-505. PubMed ID: 32393771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer.
    Zambirinis CP; Miller G
    Trends Mol Med; 2017 May; 23(5):465-481. PubMed ID: 28400243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
    Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging antibodies for the treatment of pancreatic cancer.
    Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer.
    Vennin C; Murphy KJ; Morton JP; Cox TR; Pajic M; Timpson P
    Gastroenterology; 2018 Mar; 154(4):820-838. PubMed ID: 29287624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine learning analyses of highly-multiplexed immunofluorescence identifies distinct tumor and stromal cell populations in primary pancreatic tumors.
    Vance K; Alitinok A; Winfree S; Jensen-Smith H; Swanson BJ; Grandgenett PM; Klute KA; Crichton DJ; Hollingsworth MA
    Cancer Biomark; 2022; 33(2):219-235. PubMed ID: 35213363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAK and paxillin, two potential targets in pancreatic cancer.
    Kanteti R; Batra SK; Lennon FE; Salgia R
    Oncotarget; 2016 May; 7(21):31586-601. PubMed ID: 26980710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow-derived proangiogenic cells in pancreatic cancer.
    Mizukami Y
    J Gastroenterol Hepatol; 2012 Mar; 27 Suppl 2():23-6. PubMed ID: 22320912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis and Pancreatic Cancer: Novel Approaches to Overcome Treatment Resistance.
    Grobbelaar C; Kgomo M; Mabeta P
    Curr Cancer Drug Targets; 2024; 24(11):1116-1127. PubMed ID: 38299403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory cytokines in human pancreatic cancer.
    Roshani R; McCarthy F; Hagemann T
    Cancer Lett; 2014 Apr; 345(2):157-63. PubMed ID: 23879960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.